Summary of COVID-19 silymarin studies

1. Aryan et al., Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial

50 patient silymarin late treatment RCT: 20% higher need for oxygen therapy (p=0.78) and 8% shorter hospitalization (p=0.5).
RCT 50 hospitalized COVID-19 patients showing no significant difference in symptom resolution time or hospitalization duration with nano-silymarin treatment.
Jul 2022, Phytotherapy Research, https://onlinelibrary.wiley.com/doi/10.1002/ptr.7537, https://c19p.org/aryan